JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
JCM.00193-07v1
46/2/826    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Romero, B.
Right arrow Articles by Domínguez, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Romero, B.
Right arrow Articles by Domínguez, L.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, February 2008, p. 826-827, Vol. 46, No. 2
0095-1137/08/$08.00+0     doi:10.1128/JCM.00193-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Single-Nucleotide Polymorphism in Two Representative Multidrug-Resistant Mycobacterium bovis Isolates Collected from Patients in a Spanish Hospital Harboring a Human Infection Outbreak{triangledown}


   LETTER
Top
 LETTER
REFERENCES
 
Mycobacterium bovis is the etiological agent of tuberculosis in domestic and wild animals. Its involvement as a human pathogen has been highlighted again with the recent descriptions of transmission through dairy products (18), reactivation or primary infection in human immunodeficiency virus-infected patients (5), and association with meat industry workers, animal keepers, or hunters (3). Strains resistant to antituberculous drugs (M. bovis is naturally resistant to pyrazinamide) pose an additional risk (2). Several studies have demonstrated that mutations in target genes are associated with resistance to antituberculous drugs (4, 7, 10, 11, 16). However, most of them have been developed in Mycobacterium tuberculosis strains and limited data are available regarding M. bovis isolates.

The aim of this study was to characterize by sequencing the main genes involved in antibiotic resistance in two multidrug-resistant (MDR) M. bovis isolates in a human outbreak detected in a hospital in Madrid that subsequently spread to several countries (5, 6, 15). The isolates were resistant to 11 drugs, but only their rpoB and katG genes have been analyzed so far (1, 14). We studied the first (93/R1) and last (95/R4) M. bovis isolates of this nosocomial outbreak, characterized by spoligotyping as SB0426 (hexacode 63-5F-5E-7F-FF-60 in the database at www.mbovis.org) (1, 13).

Several genes involved in resistance to isoniazid (katG, ahpC, inhA, and the oxyR-ahpC intergenic region), rifampin (rpoB), streptomycin (rrs, rpsL), ethambutol (embB), and quinolones (gyrA) were studied. These genes, or fragments of genes, were amplified and sequenced as previously described (12).

The sequence analysis revealed polymorphisms in five (ahpC, rpoB, rpsL, embB, and gyrA) out of nine analyzed genes (Table 1). Nucleotide substitutions in four genes cause a change in the encoded amino acid. Two additional synonymous mutations in ahpC and rpsL differentiated the first and last isolates from the outbreak.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Mutations in genes associated to drug resistance found in the first (93/R1) and last (95/R4) human MDR M. bovis isolates

 
The analysis of the main genes involved in isoniazid resistance did not show polymorphism involved in resistance. Both M. bovis isolates displayed a CTG codon at position 463 of the katG gene. It was initially hypothesized that this Arg463Leu change might be involved in resistance to isoniazid according to reports on M. tuberculosis isolates (9), but it was shown later that they are not associated (17). Sequencing of the ahpC gene showed that the last MDR isolate from the outbreak (95/R4) had a silent mutation at codon 70 (AAG->AAA, Lys->Lys).

The sequencing of the rpoB gene revealed a substitution mutation in codon 531 (TCG->TTG, Ser->Leu) in the two human MDR isolates (1, 14). Greater than 95% of the rifampin-resistant M. tuberculosis complex strains have mutations between codons 507 and 533 of the rpoB gene (8).

The study of two genes involved in streptomycin resistance showed no polymorphisms in rrs and two mutations in rpsL. Both human isolates had a substitution mutation with a replacement in codon 43 (AAG->AGG, Lys->Arg) that has been found in M. tuberculosis isolates with resistance to this drug, predominantly associated with a high-level resistance phenotype (7). Also, the last MDR isolate (95/R4) accumulated a silent mutation at codon 38 (TAC->TAT, Tyr->Tyr) that has not been described. In relation to ethambutol resistance, both human isolates also showed a mutation located at codon 306 (ATG->GTG, Met->Val) in the embB gene. This mutation has been described in M. tuberculosis isolates (10), but it has not been reported in M. bovis so far. The gyrA gene showed a nucleotide replacement at codon 91 (TCG->CCG, Ser->Pro), which has been described in resistant M. tuberculosis strains (4), that was associated with resistance to fluoroquinolones.

In summary, the MDR M. bovis isolates harbored nucleotide substitutions in the rpoB, rpsL, embB, and gyrA genes previously described in M. tuberculosis strains but the genetic mechanism of isoniazid resistance remains unknown. Knowledge of frequent mutations would help in the development of precise molecular tests to quickly detect resistance. However, more studies of the mutations underlying drug resistance in M. bovis strains are needed before reliable use of the rapid commercial systems available for the detection of gene mutations is possible.


   ACKNOWLEDGMENTS
 
This research was funded by project AGL 2001-2029 of the Spanish Ministry of Science and Technology and by the Spanish Ministry of Agriculture Fisheries and Food. B. Romero is the recipient of a research contract funded by Comunidad de Madrid (IV Regional Framework Program of Research and Technological Innovation 2005-2008).

We thank the staff of the SADNA (C.I.B. Madrid) for sequencing. We are grateful to M. Gilmour for careful revision of the manuscript.


   FOOTNOTES
 
{triangledown} Published ahead of print on 19 December 2007. Back


   REFERENCES
Top
 LETTER
 REFERENCES
 

  1. Blázquez, J., L. E. Espinosa de los Monteros, S. Samper, C. Martín, A. Guerrero, J. Cobo, J. van Embden, F. Baquero, and E. Gómez-Mampaso. 1997. Genetic characterization of multidrug-resistant Mycobacterium bovis strains from a hospital outbreak involving human immunodeficiency virus-positive patients. J. Clin. Microbiol. 35:1390-1393.[Abstract]
  2. Dankner, W. M., N. J. Waecker, M. A. Essey, K. Moser, M. Thompson, and C. E. Davis. 1993. Mycobacterium bovis infections in San Diego: a clinicoepidemiologic study of 73 patients and a historical review of a forgotten pathogen. Medicine 72:11-37.[Medline]
  3. de la Rua-Domenech, R. 2006. Human Mycobacterium bovis infection in the United Kingdom: incidence, risks, control measures and review of the zoonotic aspects of bovine tuberculosis. Tuberculosis 86:77-109.[CrossRef][Medline]
  4. Giannoni, F., E. Iona, F. Sementilli, L. Brunori, M. Pardini, G. B. Migliori, G. Orefici, and L. Fattorini. 2005. Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:2928-2933.[Abstract/Free Full Text]
  5. Guerrero, A., J. Cobo, J. Fortún, E. Navas, C. Quereda, A. Asensio, J. Cañón, J. Blázquez, and E. Gómez-Mampaso. 1997. Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection. Lancet 350:1738-1742.[CrossRef][Medline]
  6. Long, R., E. Nobert, S. Chomyc, J. van Embden, C. McNamee, R. R. Duran, J. Talbot, and A. Fanning. 1999. Transcontinental spread of multidrug-resistant Mycobacterium bovis. Am. J. Respir. Crit. Care Med. 159:2014-2017.[Abstract/Free Full Text]
  7. Meier, A., P. Sander, K. J. Schaper, M. Scholz, and E. C. Bottger. 1996. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:2452-2454.[Abstract]
  8. Morgan, M., S. Kalantri, L. Flores, and M. Pai. 2005. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect. Dis. 5:62.[CrossRef][Medline]
  9. Musser, J. M., V. Kapur, D. L. Williams, B. N. Kreiswirth, D. van Soolingen, and J. D. van Embden. 1996. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J. Infect. Dis. 173:196-202.[Medline]
  10. Parsons, L. M., M. Salfinger, A. Clobridge, J. Dormandy, L. Mirabello, V. L. Polletta, A. Sanic, O. Sinyavskiy, S. C. Larsen, J. Driscoll, G. Zickas, and H. W. Taber. 2005. Phenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol. Antimicrob. Agents Chemother. 49:2218-2225.[Abstract/Free Full Text]
  11. Ramaswamy, S. V., R. Reich, S. J. Dou, L. Jasperse, X. Pan, A. Wanger, T. Quitugua, and E. A. Graviss. 2003. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:1241-1250.[Abstract/Free Full Text]
  12. Romero, B., A. Aranaz, J. Bezos, J. Álvarez, L. de Juan, M. T. Javed, A. Mateos, E. Gómez-Mampaso, and L. Domínguez. 2007. Drug susceptibility of Spanish Mycobacterium tuberculosis complex isolates from animals. Tuberculosis 87:565-571.[CrossRef][Medline]
  13. Romero, B., A. Aranaz, L. de Juan, J. Álvarez, J. Bezos, A. Mateos, E. Gómez-Mampaso, and L. Domínguez. 2006. Molecular epidemiology of multidrug-resistant Mycobacterium bovis isolates with the same spoligotyping profile as isolates from animals. J. Clin. Microbiol. 44:3405-3408.[Abstract/Free Full Text]
  14. Samper, S., M. J. Iglesias, M. J. Rabanaque, L. I. Gómez, M. C. Lafoz, M. S. Jiménez, A. Ortega, M. A. Lezcano, D. van Soolingen, and C. Martín. 2005. Systematic molecular characterization of multidrug-resistant Mycobacterium tuberculosis complex isolates from Spain. J. Clin. Microbiol. 43:1220-1227.[Abstract/Free Full Text]
  15. Samper, S., C. Martín, A. Pinedo, A. Rivero, J. Blázquez, F. Baquero, D. van Soolingen, and J. van Embden. 1997. Transmission between HIV-infected patients of multidrug-resistant tuberculosis caused by Mycobacterium bovis. AIDS 11:1237-1242.[CrossRef][Medline]
  16. Telenti, A., P. Imboden, F. Marchesi, D. Lowrie, S. Cole, M. J. Colston, L. Matter, K. Schopfer, and T. Bodmer. 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341:647-650.[CrossRef][Medline]
  17. van Doorn, H. R., E. J. Kuijper, A. van der Ende, A. G. A. Welten, D. van Soolingen, P. E. W. de Haas, and J. Dankert. 2001. The susceptibility of Mycobacterium tuberculosis to isoniazid and the Arg->Leu mutation at codon 463 of katG are not associated. J. Clin. Microbiol. 39:1591-1594.[Abstract/Free Full Text]
  18. Winter, A., C. Driver, M. Macaraig, C. Clark, S. S. Munsiff, C. Pichardo, J. Jereb, P. LoBue, and M. Lynch. 2005. Tuberculosis cases caused by Mycobacterium bovis infections, New York City, 2001-2004. Morb. Mortal. Wkly. Rep. 54:605-608.[Medline]
Beatriz Romero
Alicia Aranaz*
Javier Bezos
Julio Álvarez
Lucía de Juan
Ana Mateos
Departamento de Sanidad Animal
Facultad de Veterinaria
Universidad Complutense de Madrid
28040 Madrid, Spain

Enrique Gómez-Mampaso
Servicio de Microbiología
Hospital Ramón y Cajal
IMSALUD
28034 Madrid, Spain

Lucas Domínguez
Departamento de Sanidad Animal
Facultad de Veterinaria
Universidad Complutense de Madrid
28040 Madrid, Spain

* Phone: 34 91 3943721, Fax: 34 91 3943795, E-mail: alaranaz{at}vet.ucm.es

Journal of Clinical Microbiology, February 2008, p. 826-827, Vol. 46, No. 2
0095-1137/08/$08.00+0     doi:10.1128/JCM.00193-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
JCM.00193-07v1
46/2/826    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Romero, B.
Right arrow Articles by Domínguez, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Romero, B.
Right arrow Articles by Domínguez, L.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS